Presentation is loading. Please wait.

Presentation is loading. Please wait.

Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles  Mayte Suárez-Fariñas,

PublishΣωσιγένης Ελευθεριάδης Modified over 5 years ago

Similar presentations

Presentation on theme: "Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles  Mayte Suárez-Fariñas,"— Presentation transcript:

1 Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles  Mayte Suárez-Fariñas, PhD, Maria Suprun, MPH, Helena L. Chang, MS, Gustavo Gimenez, BS, Galina Grishina, MS, Robert Getts, PhD, Kari Nadeau, MD, Robert A. Wood, MD, Hugh A. Sampson, MD  Journal of Allergy and Clinical Immunology  Volume 143, Issue 3, Pages (March 2019) DOI: /j.jaci Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Journal of Allergy and Clinical Immunology 2019 143, 1038-1046DOI: (10
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 1 Changes induced by MOIT in epitope-specific IgE or IgG4 binding by adjuvant treatment arm. A, Heat map representing (standardized) binding of 108 epitopes (48 IgE and 60 IgG4), with significant changes (fold change [FCH] > 1.5 and FDR ≤ 0.05) at month 32 from baseline. B, Box plot of the MOIT-induced log2 FCHs in epitope binding by adjuvant treatment. C, Bar plots of MOIT-induced changes and 95% CIs in log10 levels of SCPs. Asterisks represent a significant change at month 32 from baseline: *P < .05, **P < .01, and ***P < .001. DS, Desensitization; β-LG, β-lactoglobulin. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 2 Changes in ESAB by adjuvant treatment and MOIT outcome. A and B, Bar plots representing changes induced by MOIT in patients achieving only desensitization (DS) or SU by adjuvant treatment arm for each IgE and IgG4 epitope. The height of the bars represents the log2 fold change (FCH) in binding from baseline to month 32. Colors represent the direction of change (red, increase; blue, decrease) for the differential epitope-specific antibody binding (DESAB; FCH > 1.5 and FDR < 0.05). Colored asterisks indicate significance in changes between SU and DS outcomes for each adjuvant treatment (light blue, placebo; light pink, omalizumab); black asterisks represent DESAB, with significant differences between omalizumab and placebo for each outcome. C, Box plot of MOIT-induced changes in ESAB by MOIT outcome. NR, Nonresponder. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 3 Differences in baseline epitope and SCP levels between groups achieving desensitization (DS) or SU 8 weeks after MOIT discontinuation. A, Box plots of the baseline overall (z score) epitope-specific IgE binding by MOIT outcome, with significantly different z scores between the SU and DS groups. NR, Nonresponders. B, Heat map representing baseline epitope-specific IgE binding for each patient for the set of epitopes with significant differences (fold change [FCH] > 1.5 and FDR < 0.05) between DS and SU outcomes at baseline. β-LG, β-Lactoglobulin. C, Bar plots of the least square mean (lsmean) with the 95% CI of log10 SCP levels at baseline by MOIT outcome. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 4 Prediction of desensitization (DS) versus SU outcome at month 32 (8 weeks after MOIT discontinuation) by using baseline levels with machine learning algorithms. A, Performance metrics of models fitted with different features: epitope-specific IgE or IgG4 binding only, SCPs (total IgE; milk-specific IgE; casein-specific IgE, IgG, and IgG4; and β-lactoglobulin–specific IgE and IgG), or the combination of SCPs and IgE and IgG4 epitopes in 300 bootstrapping simulations. Means and 95% CIs are presented. IgE epitopes are sufficient to achieve maximal predictive performance. Accuracy and receiver operating characteristic (ROC) curve are presented here; other metrics can be found in Fig E8. B, ROC curve and coefficients for the best model with the 6 most robust IgE epitopes identified as important predictors in at least 75% of the bootstrapping simulations (BF = 75%). C, Predicted probabilities (x-axis) versus actual MOIT outcomes of all subjects (colored bars) as predicted by using an IgE-based epitope model with a BF of 75%. If the predicted probability is greater than 0.5, the subject is classified as SU and DS otherwise. Pink and red bars represent actual MOIT outcomes: DS (pink) and SU (red). D, Performance metrics of 4 models, including epitopes with BFs of 60% to 80%. Estimates with 95% CIs are presented for cross-validation (CV) statistics. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles  Mayte Suárez-Fariñas,"

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
The natural history of soy allergy

The natural history of soy allergy
The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy  Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy  Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.
Corinne A. Keet, MD, MS, Pamela A

Corinne A. Keet, MD, MS, Pamela A
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.
Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.
An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis  Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,

An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis  Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,
Advances in food allergy in 2015

Advances in food allergy in 2015
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis  Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis  Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,
Early recovery from cow's milk allergy is associated with decreasing IgE and increasing IgG4 binding to cow's milk epitopes  Emma M. Savilahti, MD, Ville.

Early recovery from cow's milk allergy is associated with decreasing IgE and increasing IgG4 binding to cow's milk epitopes  Emma M. Savilahti, MD, Ville.
Correlation of IgE/IgG4 milk epitopes and affinity of milk-specific IgE antibodies with different phenotypes of clinical milk allergy  Julie Wang, MD,

Correlation of IgE/IgG4 milk epitopes and affinity of milk-specific IgE antibodies with different phenotypes of clinical milk allergy  Julie Wang, MD,
Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy  Pamela A. Frischmeyer-Guerrerio, MD,

Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy  Pamela A. Frischmeyer-Guerrerio, MD,
Decreased response to inhaled steroids in overweight and obese asthmatic children  Erick Forno, MD, MPH, Rachel Lescher, MD, Robert Strunk, MD, Scott Weiss,

Decreased response to inhaled steroids in overweight and obese asthmatic children  Erick Forno, MD, MPH, Rachel Lescher, MD, Robert Strunk, MD, Scott Weiss,
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

Similar presentations

Ads by Google